Alps Group Inc Nov 22, 2026 Copy link Alps Group Inc Regains Compliance with Nasdaq Minimum Bid Price Requirement KUALA LUMPUR, Malaysia, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an Business
Alps Group Inc Nov 12, 2026 Copy link Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing PCI Positions MyGenome as Southeast Asia's Reference Laboratory for Drug Interaction Safety Science Business
Alps Group Inc Oct 30, 2026 Copy link Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an Business
Alps Group Inc Aug 7, 2026 Copy link Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Business
Alps Group Inc Jun 23, 2026 Copy link Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Business
Alps Group Inc Jun 9, 2026 Copy link Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022 MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Business
Alps Group Inc Apr 17, 2026 Copy link Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent Business